Rosiglitazone Decreases Plasma Levels of Osteoprotegerin in a Randomized Clinical Trial with Type 2 Diabetes Patients

Biomarkers of the Osteoprotegerin Pathway

(2010) Wolfgang Lieb et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Increases Bone Resorption in Women with Type 2 Diabetes: A Randomized, Controlled Trial

(2010) Ugis Gruntmanis et al.   CALCIFIED TISSUE INTERNATIONAL

Pharmacological Treatment of the Pathogenetic Defects in Type 2 Diabetes: The randomized multicenter South Danish Diabetes Study

(2010) J. Gram et al.   DIABETES CARE

Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus

(2010) Jong Suk Park et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

RANKL Increases Vascular Smooth Muscle Cell Calcification Through a RANK-BMP4–Dependent Pathway

(2009) Sara Panizo et al.   CIRCULATION RESEARCH

Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations from A Diabetes Outcome Progression Trial (ADOPT)

(2009) S. E. Kahn et al.   DIABETES CARE

Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity

(2009) Gitte Maria Jørgensen et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes

(2009) Bernard Zinman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Hyperglycaemia and coronary heart disease: the meta picture

(2009) Theodore Mazzone   LANCET

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

(2009) Philip D Home et al.   LANCET

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

(2009) Kausik K Ray et al.   LANCET

Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women

(2009) Iraj Nabipour et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)

(2008) Michel Komajda et al.   Cardiovascular Diabetology

The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review

(2008) Mads Nybo et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY